MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $13.1B— | $11.9B-9.7% | $12.2B+2.5% | $13.0B+7.0% | $14.0B+7.2% |
| EPS (dil.) | $24.38— | $13.96-42.7% | $4.77-65.8% | $8.84+85.3% | $10.46+18.3% |
| Free Cash Flow | $2.6B— | $1.5B-44.4% | $874M-40.7% | $1.1B+25.4% | $1.2B+10.0% |
| Gross Margin | 38.0% | 31.3%-6.7pp | 27.7%-3.6pp | 27.9%+0.2pp | 26.8%-1.1pp |
| Operating Margin | 23.2% | 12.1%-11.1pp | 6.0%-6.1pp | 8.4%+2.4pp | 10.9%+2.5pp |
| Net Margin | 18.1% | 10.8%-7.3pp | 3.4%-7.3pp | 5.7%+2.3pp | 6.3%+0.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $334 (last qtr, 5 analysts) → $334 (last mo, 5) (+0.0%).
Buy-rated share 75% → 72% over ~3 months (-3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $4.78 | $4.99 | +4.4% |
| Apr 2026 | $4.11 | $4.25 | +3.4% |
| Feb 2026 | $3.95 | $4.07 | +3.0% |
| Oct 2025 | $4.13 | $4.18 | +1.2% |
| Jul 2025 | $4.17 | $4.35 | +4.3% |
| Apr 2025 | $3.74 | $3.84 | +2.7% |
| Feb 2025 | $3.39 | $3.45 | +1.8% |
| Oct 2024 | $3.47 | $3.50 | +0.9% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$7.9M over 180 days (0 open-market buys, 14 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 0.8%/yr (revenue basis).
Base free cash flow $1.1B (avg FY2023–FY2025; latest year $1.2B) · equity value $26.6B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 58 for Labcorp Holdings indicates a moderately favorable outlook, driven by strong momentum with a 12-month return of 20.4% and a 3-month return of 27.5%. The stock's momentum and low risk scores, with a beta of 0.8, contribute to its relatively high QScore, while its value and growth scores are more neutral due to a P/E of 26.6 and revenue growth of 7.2%. The short-term score is slightly higher than the long-term score, suggesting some near-term optimism.